Drug Profile
Bevacizumab biosimilar - Polpharma
Alternative Names: bevacizumab mAb - EPIRUS; BOW 030Latest Information Update: 29 Mar 2023
Price :
$50
*
At a glance
- Originator EPIRUS Biopharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Mar 2023 Discontinued - Preclinical for Cancer in USA (Parenteral)
- 28 May 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)